Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>FY09/24 results: Revenue JPY80mn (+15.6% YoY), operating loss JPY818mn, net loss JPY756mn, SG&A expenses JPY898mn.</li><li>FY09/25 forecast: Revenue JPY272mn (+239.8% YoY), SG&A expenses JPY1.6bn, operating loss JPY1.4bn, net loss JPY1.4bn.</li><li>Current assets JPY2.8bn, liabilities JPY649mn, net assets JPY2.1bn; capital increases from stock acquisition rights.</li></ul>

FY09/24 results: Revenue JPY80mn (+15.6% YoY), operating loss JPY818mn, net loss JPY756mn, SG&A expenses JPY898mn.FY09/25 forecast: Revenue JPY272mn (+239.8% YoY), SG&A expenses JPY1.6bn, operating loss JPY1.4bn, net loss JPY1.4bn.Current assets JPY2.8bn, liabilities JPY649mn, net assets JPY2.1bn; capital increases from stock acquisition rights.

Kringle Pharma Inc (4884 JP): Full-year FY09/24 flash update

<ul><li>**Q3 FY09/24 Financial Results:** Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn.</li><li>**Revised FY09/24 Forecast:** Sales JPY79mn, operating loss JPY1.0bn, recurring loss JPY940mn, net loss JPY942mn, net loss per share JPY147.23.</li><li>**Financial Position Changes:** Current assets JPY2.9bn, current liabilities JPY84mn, fixed liabilities JPY517mn, net assets JPY2.3bn, capital stock JPY516mn.</li></ul>

**Q3 FY09/24 Financial Results:** Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn.**Revised FY09/24 Forecast:** Sales JPY79mn, operating loss JPY1.0bn, recurring loss JPY940mn, net loss JPY942mn, net loss per share JPY147.23.**Financial Position Changes:** Current assets JPY2.9bn, current liabilities JPY84mn, fixed liabilities JPY517mn, net assets JPY2.3bn, capital stock JPY516mn.

Kringle Pharma Inc (4884 JP): Q3 FY09/24 flash update

Japan

Kringle Pharma, Inc. develops and distributes biotechnology products. The Company produces regenerative medicines, cancer therapy medicines, and other products. Kringle Pharma markets its products throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kringle Pharma Inc (4884 JP)